Pancreatic amylase is the enzyme produced in the pancreatic tissue, which helps in the digestion of starch from the ingested food. Pancreatic amylase reagent assay performed for the quantitative determination of pancreatic amylase in the plasma and serum. This pancreatic amylase reagent assay based upon the colorimetric method. Normally pancreatic amylase reagent used to diagnose the acute and chronic pancreatitis. Pancreatic amylase reagent also used to diagnose the perforated ulcers, gall bladder diseases, mumps or ectopic pregnancy. Pancreatic amylase reagent used to activate the two monoclonal antibodies in the serum or plasma, this activates antibodies increases the light absorbance of the sample. The absorbed light wavelength help to identify the pancreatic amylase in the sample. Normal pancreatic amylase level in the body ranges from 19 units per liter (U/L) and 86 U/L., however, the proper pancreatic amylase regent should be used during the test to achieve the good result. pancreatic amylase regent kit includes Sodium phosphate, monobasic buffer, Sodium chloride, Starch from potato, Sodium hydroxide, Potassium sodium tartrate, 3,5-Dinitrosalicylic acid.
Rising patient pool suffering from the acute and chronic pancreatic disorders may drive the pancreatic amylase reagent market. People suffering from the disorders like indigestion, gastroesophageal reflux disease (GERD) may show the fueling growth for pancreatic amylase reagent market. Disease conditions like persistent diarrhea, vitamin deficiency, malnutrition will show the additional demand of the pancreatic amylase reagent market. In children cystic fibrosis (CF) or Shwachman-Diamond Syndrome (SDS) diagnosis may show the propelling growth for pancreatic amylase reagent market. Alternative diagnosis methods like CT scan, Endoscopy for the pancreatic testing may show the slower growth for pancreatic amylase reagent market. Awareness of the people about the cystic fibrosis and pancreatic cancer may show the stagnancy in the pancreatic amylase reagent market.
The global pancreatic amylase reagent market is classified on the basis of application, end user and region.
Based on indication, pancreatic amylase reagent market is segmented into the following:
Based on end user, pancreatic amylase reagent market is segmented into the following:
Rising population of the pancreatic disorders is the main factor for the growth of pancreatic amylase reagent market, however by indication type, pancreatic disorders expected to show the good revenue for the pancreatic amylase reagent market. Cancer segment covers the various cancer related to the GIT, such as intestine cancer, stomach cancer etc., rising patient pool of gall bladder related complications and cancers expected to fuel the growth of the pancreatic amylase reagent market.
In the developing countries like India, South Africa & Brazil people suffering from the cystic fibrosis, in such scenarios cystic fibrosis diagnosis will show the good revenue for the pancreatic amylase reagent market. By end user, hospitals segment expected to the high revenue share for the pancreatic amylase reagent market, since the majority of population visiting to the hospitals is high, for the diagnosis of various disorders. Followed by the hospitals clinics wills show the good revenue for the pancreatic amylase reagent market, since people normally visits the specialty clinics for the GIT related complications. Diagnostic center segment will show the lucrative growth in a developed countries for pancreatic amylase reagent market, due to the more number of diagnostic and pathology labs in the developed countries, and people also visits for the routine body check up in the diagnostic center. In comparison to all the above end user, research centers may show the slower growth for pancreatic amylase reagent, since the very narrow level test reagent may requires on the occasional purpose.
Among the regional presence, North America will show the high revenue for the pancreatic amylase reagent market, since the people are more concern about the GIT track related complications. After North America, the Europe region will show the propelling growth for a pancreatic amylase reagent market in the near future, since the good hospital infrastructure and more number of hospitals in the Europe region. Latin America region will show the good demand for the pancreatic amylase reagent market, due to the regional government imitative towards the public health care program, Brazil market will be the most lucrative market for pancreatic amylase reagent. In Asian countries like China and India, the rate of the colon and rectum cancer is high due to the lifestyle pattern and unhygienic conditions, this condition may show the additional demand for the pancreatic amylase reagent market. The Middle East and Africa are expected to account for being the least lucrative market for pancreatic amylase reagent due to lack of awareness about the chymotrypsin test-related disorders in people.
Some of the key players across the value chain of pancreatic amylase reagent market are DIALAB GmbH, DiaSys Diagnostic Systems GmbH, Sunson Industry Group Co.,Ltd, Randox Laboratories Ltd., Abbott, Beckman Coulter, Inc., Biocompare, Vitro Scient Co., Merck KGaA., Sisco Research Laboratories Pvt. Ltd. Biosystems S.A. and others.
The report on Pancreatic Amylase Reagent market covers exhaustive analysis on:
Regional analysis for Pancreatic Amylase reagent market includes
Report on Pancreatic Amylase reagent market highlights: